Inpyrfluxam 

Inpyrfluxam is a succinate dehydrogenase (SDH) inhibitor. Inpyrfluxam targets the ubiquinone binding pocket of mitochondrial SDH complex subunits ViSDHB, ViSDHC, ViSDHD, interfering with cellular respiration. Inpyrfluxam inhibits conidial germination and mycelial growth of Venturia inaequalis in vitro. Inpyrfluxam can be used for the research of apple scab^[1].

Inpyrfluxam (0.001-10 μg/mL; 1 week) inhibits conidial germination of baseline Venturia inaequalis isolates with a mean EC₅₀ of 0.0137 μg/mL^[1].
Inpyrfluxam (0.001-10 μg/mL; 3 weeks) inhibits mycelial growth of baseline Venturia inaequalis isolates with a mean EC₅₀ of 0.0291 μg/mL^[1].
Inpyrfluxam (0.0137-0.137 μg/mL; 1-4 weeks) shows significant positive cross-sensitivity with all tested SDH fungicides in Venturia inaequalis, with the strongest correlation for both conidial germination and mycelial growth inhibition observed with Benzovindiflupyr^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

333.38

C₁₈H₂₁F₂N₃O

1352994-67-2

N(C(=O)C=1C(C(F)F)=NN(C)C1)C2=C3C(C(C)(C)C[C@H]3C)=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ayer KM, et al. Characterization of the VisdhC and VisdhD genes in Venturia inaequalis, and sensitivity to fluxapyroxad, pydiflumetofen, inpyrfluxam, and benzovindiflupyr. Plant disease. 2019 Jun 16;103(6):1092-100.